EXOZ

eXoZymes Inc

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 100%
Negative

Neutral
Accesswire
19 days ago
Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees
LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 30, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced that two of its senior leaders - CCO Damien Perriman and VP of Development, Dr. Paul Opgenorth - have been elected to key roles within the BioMADE Governance Committees. Chief Commercial Officer at eXoZymes, Damien Perriman, states, "Being elected to the BioMADE Leadership Council is both an honor and a responsibility.
Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees
Neutral
Accesswire
2 months ago
eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today
Management to host earnings call at 5:00PM Eastern Time, today. LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar at 5:00 PM Eastern Time to provides an update on operations through the fiscal quarter that ended June 30, 2025.
eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today
Neutral
Accesswire
2 months ago
eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST
LOS ANGELES, CA / ACCESS Newswire / August 7, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Tuesday, August 12, 2025 at 5:00 PM Eastern Time to discuss its results for the second quarter of 2025. Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session.
eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST
Neutral
Accesswire
2 months ago
eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity
Using eXoZymes' AI-driven exozymes platform, NCTx has demonstrated lab scale validation with 4 grams of NCT produced at a 96% yield and with a purity higher than 99%. NCT project went from concept to gram scale production in 5 months and at a fraction of normal SynBio R&D cost.
eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity
Neutral
Accesswire
2 months ago
eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months
N-trans-caffeoyltyramine (NCT) is a natural bioactive compound attracting considerable interest from researchers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity. Using eXoZymes' AI-driven platform, a new and proprietary approach to biomanufacturing of NCT - with all the scale-up advantages of an exozyme biosolution - has been developed: Progressing from concept to lab scale validation with gram-scale production in only 5 months and at a fraction of normal SynBio R&D cost.
eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months
Neutral
Accesswire
3 months ago
eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing
MONROVIA, CA / ACCESS Newswire / June 26, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its role in the Meta-PURE initiative, a $9.2 million USD National Science Foundation (NSF) funded project under the CFIRE program aimed at transforming the scalability and accessibility of cell-free systems to expand real-world applications. Led by Georgia Tech with a coalition of top academic and industry groups, Meta-PURE will build a suite of standardized, interoperable ‘modules' for cell-free biomanufacturing, enabling plug-and-play modules that can rapidly shift between use cases - from high-value nutraceuticals, to essential chemicals or pharmaceuticals.
eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing
Neutral
Accesswire
5 months ago
eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast
MONROVIA, CALIFORNIA / ACCESS Newswire / May 16, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - was featured on the latest episode of the Grow Everything podcast, revealing how the company's AI-engineered exozymes are reshaping the next generation of biomanufacturing by enabling sustainable chemical production outside of living cells. Considered one of the leading podcasts in biotechnology, the Grow Everything podcast is co-hosted by biotech experts, Erum Azeez Khan and Karl Schmieder, M.S.
eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast
Neutral
Accesswire
5 months ago
eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today
Management to host  earnings call at 5:00PM Eastern Time, today. MONROVIA, CA / ACCESS Newswire / May 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential nutraceuticals, medicines, biofuels, and other valuable chemicals - provides an update on operations through the fiscal quarter that ended March 31, 2025, as well as the launch of the purpose-built subsidiary, NCTx.
eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today
Neutral
Accesswire
5 months ago
eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST
MONROVIA, CA / ACCESS Newswire / May 7, 2025 / eXoZymes Inc. (NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Monday, May 12, 2025 at 5:00 PM Eastern Time to discuss its results for the first quarter of 2025, as well as share more details around the newly formed purpose-built subsidiary, NCTx. Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session.
eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST
Neutral
Accesswire
5 months ago
eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health
N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity. eXoZymes used its AI-driven development platform to progress from idea to purpose-built subsidiary in less than 3 months and at a fraction of normal SynBio R&D cost.
eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health